SCHEMBL10102632

SCHEMBL10102632

OCCCc1cc2cc(OC(F)(F)F)ccc2nc1-c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DHFR P00374 3/20 0.41
DHODH Q02127 1/20 0.40
CYP11B1 P15538 1/20 0.40
CYP11B2 P19099 1/20 0.40
RUNX1 Q01196 1/20 0.40
PTGFR P43088 2/20 0.39
PIM1 P11309 1/20 0.39
NAMPT P43490 3/20 0.38
KMT2A Q03164 1/20 0.36
ATM Q13315 1/20 0.36
CBFB Q13951 1/20 0.35
PDE10A Q9Y233 1/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.35
PDE2A O00408 1/20 0.35
PDE3B Q13370 1/20 0.35
PDE3A Q14432 1/20 0.35
P2RY12 Q9H244 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10102660 0.84 IDO1 (0.44) RUNX1
SCHEMBL3383001 0.82 DHODH (0.45) DHFRDHODHKMT2AATM
SCHEMBL10102670 0.78 PSMB5 (0.47) DHODHPTGFRKMT2AATMPDE10A
SCHEMBL28170329 0.77 PDE10A (0.58) DHFRDHODHRUNX1PTGFRKMT2A
SCHEMBL13005210 0.77 AKT1 (0.39) DHODHPTGFRKMT2AATMPDE10A
SCHEMBL10102628 0.76 DHODH (0.46) DHODHKMT2AATMPDE10A
SCHEMBL10102635 0.75 PSMB5 (0.39) DHODHPTGFRKMT2AATMPDE10A
SCHEMBL10102630 0.75 KMT2A (0.38) CYP11B1CYP11B2KMT2AATMPDE10A
SCHEMBL10102671 0.74 DHODH (0.46) DHFRDHODH
SCHEMBL13005263 0.71 DHFR (0.40) DHFRDHODHNAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207345-B2 Antitumor agents; use in combination with other drugs such as pentamidine MERCK PATENT GMBH (DE) 2012-06-26 US disclosed
US-8207345-B2 Antitumor agents; use in combination with other drugs such as pentamidine MERCK PATENT GMBH (DE) 2012-06-26 US disclosed
EP-1891011-B1 TETRAHYDROQUINOLINES USED IN THE FORM OF MODULATORS OF MITOTIC MOTOR-PROTEINS EG5 MERCK PATENT GMBH (DE) 2010-12-08 EP disclosed
US-20080200451-A1 Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 MERCK PATENT GMBH (DE) 2008-08-21 US disclosed
US-20080200451-A1 Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 MERCK PATENT GMBH (DE) 2008-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200451-A1 Tetrahydroquinolines for Use as Modulators of the Mitotic Motor Protein Eg5 KIF5A, KIF5C, KIF5B DHFR 419/4885DHODH 961/4885CYP11B1 3543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.